Committee on Clinical Pharmacology & Pharmacogenomics, University of Chicago, Chicago, IL, 60637, USA.
Current affiliation: Department of Pharmacogenetics, Base10 Genetics, Chicago, IL 60603, USA.
Pharmacogenomics. 2019 Jul;20(11):813-827. doi: 10.2217/pgs-2019-0040.
Several high-profile examples of adverse outcomes from medications used in the perioperative setting are well known (e.g., malignant hyperthermia, prolonged apnea, respiratory depression, inadequate analgesia), leading to an increased understanding of genetic susceptibilities underlying these risks. Pharmacogenomic information is increasingly being utilized in certain areas of medicine. Despite this, routine preoperative genetic screening to inform medication risk is not yet standard practice. In this review, we assess the current readiness of pharmacogenomic information for clinical consideration for several common perioperative medications, including description of key pharmacogenes, pharmacokinetic implications and potential clinical outcomes. The goal is to highlight medications for which emerging or considerable pharmacogenomic information exists and identify areas for future potential research.
一些在围手术期使用的药物导致严重不良后果的案例已广为人知(例如恶性高热、呼吸暂停延长、呼吸抑制、镇痛不足),这使人们对这些风险的遗传易感性有了更深入的了解。药物基因组学信息在医学的某些领域得到了越来越多的应用。尽管如此,用于告知药物风险的常规术前遗传筛查尚未成为标准做法。在这篇综述中,我们评估了几种常见围手术期药物的药物基因组学信息用于临床考虑的现状,包括关键药物基因的描述、药代动力学的影响和潜在的临床结果。其目的是突出具有新出现或大量药物基因组学信息的药物,并确定未来潜在研究的领域。